mProX™ Human LILRB5 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

LILRB5, a gene associated with statin intolerance and statin-induced myalgia, has various applications in clinical trials and pharmacogenomic studies. In a clinical trial, the LILRB5 Asp247Gly genotype was found to modify the cholesterol-lowering effect of statins, with individuals carrying the Asp247Asp genotype experiencing a greater increase in creatine kinase and a lower reduction in non-HDL cholesterol compared to those with the Gly247Gly genotype. This suggests that the LILRB5 variant could be used for precision cardiovascular therapy. In another study, LILRB5 was identified as one of the genetic variants associated with statin-associated muscle symptoms (SAMS) in patients receiving atorvastatin or rosuvastatin. The study found a synergistic effect between LILRB5 and ABCB1 variants on statin response, indicating that these variants could be used to predict statin efficacy. Additionally, LILRB5 has been studied in the context of repetitive low-level blast exposure, where it was found to be downregulated in experienced breachers compared to unexposed controls. This suggests that LILRB5 may play a role in the immune response to blast exposure. Furthermore, LILRB5 expression has been analyzed in liver cancer, with downregulation of LILRB5 observed in liver cancer tissues. The expression of LILRB5 and other LILRB family members was associated with the prognosis of liver cancer patients and the infiltration of immune cells in the tumor microenvironment. These findings highlight the potential utility of LILRB5 in predicting statin response, understanding immune response in blast exposure, and assessing prognosis in liver cancer.